Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 Combination in Platinum-Sensitive Recurrent Ovarian Cancer
NCT06990516Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2030
- Countries
- 1
- Sponsor
- Tongji Hospital
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Conditions
- ovarian cancer
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan in ovarian cancer, sponsored by Tongji Hospital. Primary endpoint: Objective Response Rate at 5 years. Planned start Jun 2025; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
SHR-A1811 Combination
SHR-A1811 + Carboplatin/Oxaliplatin + Bevacizumab
03
Who it enrols
Patients with platinum-sensitive recurrent epithelial ovarian cancer who have received 1-3 prior platinum regimens and a PARP inhibitor (if BRCA/HRD positive). Must have measurable disease and adequate organ function. Excludes prior anti-HER2 or topoisomerase I inhibitor therapy.
04
Endpoints
Primary
Objective Response Rate
Secondary
Duration of Response
Disease Control Rate
Response Rate
CA-125 Response Rate
Progression-Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT06990516.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990516.